Contineum Therapeutics, Inc. Class A (CTNM) Price & Analysis

Compare

201 Followers

CTNM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.35 - $20.24

Previous CloseN/A

Volume54.82K

Average Volume (3M)241.50K

Market Cap

$310.70M

Enterprise Value-$66.93M

Total Cash (Recent Filing)$175.48M

Total Debt (Recent Filing)$5.75M

Price to Earnings (P/E)―

Beta0.72

Next Earnings

Nov 05, 2025

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.62

Shares Outstanding21,625,223

10 Day Avg. Volume128,480

30 Day Avg. Volume241,501

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.22

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit847.18

Enterprise Value/Ebitda1.14

Forecast

1Y Price Target

$23.60

Price Target Upside113.00% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsPIPE-791 achieved meaningful receptor occupancy in both healthy volunteers and patients with progressive MS, indicating promising potential in its treatment effectiveness.

Market PositionContineum expects its undisclosed planned once-daily dose for its Phase II study of PIPE-791 in IPF will exceed the EC90 of receptor occupancy even at trough concentrations, providing a potential competitive advantage to its rivals.

Product DevelopmentPIPE-791 program may emerge as best-in-class with improved pharmacology, suggesting a competitive edge in the market.

Bears Say

Study DelaysThe company has decided to delay advancement of PIPE-791 into a Phase II study for progressive multiple sclerosis, which might slow down its market readiness.

Contineum Therapeutics, Inc. Class A News

Leerink bullish on Contineum, initiates with an Outperform

As previously reported, Leerink initiated coverage of Contineum (CTNM) with an Outperform rating and $20 price target. Idiopathic...

13d ago

BMY

CTNM

Contineum initiated with an Outperform at Leerink

Leerink initiated coverage of Contineum (CTNM) with an Outperform rating and $20 price target Published first on TheFly...

13d ago

CTNM

Contineum announces topline data from PIPE-791 trial

Contineum (CTNM) announced topline data from its PIPE-791 Phase 1b positron emission tomography trial. The trial met its...

20d ago

CTNM

Buy Rating for Contineum Therapeutics Driven by Strategic Positioning and Enhanced Efficacy in IPF Market

Contineum Therapeutics, Inc. Class A (CTNM) has received a new Buy rating, initiated by Leerink Partners analyst, Faisal...

13d ago

CTNM

Promising Potential of PIPE-791: Buy Rating for Contineum Therapeutics Amid Positive Phase 1b Results

Sean Laaman, an analyst from Morgan Stanley, maintained the Buy rating on Contineum Therapeutics, Inc. Class A. The...

19d ago

CTNM

Buy Rating for Contineum Therapeutics’ PIPE-791: Promising Phase 1b Results and Competitive Edge

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on CTNM stock, giving a Buy rating today. Debanjana...

20d ago

CTNM

Contineum Therapeutics Announces Positive Phase 1b Trial Results

An update from Contineum Therapeutics, Inc. Class A ( ($CTNM) ) is now available. On September 18, 2025,...

20d ago

CTNM

3 Best Stocks to Buy Now, 8/19/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

2M ago

WIX

CTNM

Contineum Therapeutics Reports Q2 2025 Results and Clinical Progress

Contineum Therapeutics, Inc. Class A ( ($CTNM) ) has released its Q2 earnings. Here is a breakdown of...

2M ago

CTNM

Strategic Focus on PIPE-791 Drives Buy Rating for Contineum Therapeutics

William Blair analyst Myles Minter has maintained their bullish stance on CTNM stock, giving a Buy rating today....

2M ago

CTNM

Contineum reports Q2 EPS (62c), consensus (41c)

“We continue to make significant progress with our lead programs and have taken several important steps to focus...

2M ago

CTNM

Contineum Therapeutics Holds 2025 Annual Stockholders Meeting

Contineum Therapeutics, Inc. Class A ( ($CTNM) ) has issued an announcement. On June 26, 2025, Contineum Therapeutics,...

3M ago

CTNM

Positive Outlook for Contineum Therapeutics Amidst Minor Trial Delays

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on CTNM stock, giving a Buy rating on June...

4M ago

CTNM

Contineum completes enrollment for cohorts of PIPE-791 trial

Contineum (CTNM) announced an update on its Phase 1b positron emission tomography trial of PIPE-791, a selective antagonist...

4M ago

CTNM

CTNM FAQ

What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?

Contineum Therapeutics, Inc. Class A lowest stock price was $3.35 and its highest was $20.24 in the past 12 months.

What is Contineum Therapeutics, Inc. Class A’s market cap?

Contineum Therapeutics, Inc. Class A’s market cap is $310.70M.

When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?

Contineum Therapeutics, Inc. Class A’s upcoming earnings report date is Nov 05, 2025 which is in 28 days.

How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?

Contineum Therapeutics, Inc. Class A released its earnings results on Aug 05, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.44 by -$0.18.

Is Contineum Therapeutics, Inc. Class A overvalued?

According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Contineum Therapeutics, Inc. Class A pay dividends?

Contineum Therapeutics, Inc. Class A does not currently pay dividends.

What is Contineum Therapeutics, Inc. Class A’s EPS estimate?

Contineum Therapeutics, Inc. Class A’s EPS estimate is -0.48.

How many shares outstanding does Contineum Therapeutics, Inc. Class A have?

Contineum Therapeutics, Inc. Class A has 21,625,223 shares outstanding.

What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?

Contineum Therapeutics, Inc. Class A reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.44. Following the earnings report the stock price went up 5.5%.

Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?

Currently, no hedge funds are holding shares in CTNM

Contineum Therapeutics, Inc. Class A Stock Smart Score

Neutral

Fundamentals

Return on Equity

-29.24%

Trailing 12-Months

Asset Growth

-17.38%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Contineum Therapeutics, Inc. Class A

Contineum Therapeutics, Inc. Class A (CTNM) is a biotechnology company focused on the development and commercialization of innovative therapies aimed at treating rare and complex diseases. The company operates primarily in the biopharmaceutical sector, with a strong emphasis on research and development of novel drug candidates. Contineum Therapeutics leverages cutting-edge technology and advanced scientific methods to address unmet medical needs, striving to deliver transformative treatments to patients worldwide.

Contineum Therapeutics, Inc. Class A (CTNM) Earnings & Revenues

Historic Earnings Reports

CTNM Stock 12 Month Forecast

Average Price Target

$23.60

▲(113.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","9":"$9","16":"$16","23":"$23","30":"$30"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9,16,23,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.17,12.541538461538462,13.913076923076922,15.284615384615384,16.656153846153845,18.027692307692305,19.39923076923077,20.77076923076923,22.14230769230769,23.513846153846153,24.885384615384616,26.256923076923073,27.628461538461536,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.17,12.126153846153846,13.082307692307692,14.038461538461538,14.994615384615384,15.950769230769232,16.90692307692308,17.863076923076925,18.81923076923077,19.775384615384617,20.731538461538463,21.68769230769231,22.643846153846155,{"y":23.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.17,11.849230769230768,12.528461538461539,13.207692307692307,13.886923076923077,14.566153846153846,15.245384615384616,15.924615384615384,16.603846153846153,17.283076923076923,17.962307692307693,18.64153846153846,19.32076923076923,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.25,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.25,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.7,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.04,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.97,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >